OBJECTIVE: To systematically evaluate the clinical efficacy and safety of lamotrigine combined with sodium valproate in the treatment of seizure. METHODS: PubMed

the Cochrane Library

Embase

CNKI

Wanfang database and VIP database were retrieved to collect the randomized controlled trials of lamotrigine combined with sodium valproate in the treatment of seizure（ the study group was treated with lamotrigine combined with sodium valproate

while the control group received sodium valproate）. The retrieval time was from the establishment of the database to Jan. 2021. The modified Jadad scale was used to evaluate the quality of the literature

efficiency

seizure frequency

seizure duration and high-sensitivity C-reactive protein levels were extracted as the parameters. Meta-analysis

sensitivity analysis and publication bias test were performed by using Rev Man 5. 3 software. RESULTS: A total of 18 randomized controlled trials that met the criteria were included in the literature

with a total of 1 430 cases（ 713 in the study group and 717 in the control group）. Meta-analysis results showed that the differences of total effective rate（ OR = 3. 90

95% CI = 2. 85-5. 33

Z = 8. 51

P < 0. 000 01） and seizure duration（ MD =-3. 27

95% CI =-3. 59--2. 95

Z = 20. 16

P <0. 000 01）

seizure frequency（ MD =-1. 82

95% CI =-2. 21--1. 43

Z = 9. 17

P < 0. 000 01） and high-sensitivity Creactive protein level（ MD =-3. 79

95% CI =-4. 05--3. 53

Z = 28. 65

P < 0. 000 01） in two groups were statistically significant

and the levels of above indicators in the study group were significantly better than those in the control group. The incidence of adverse drug reactions in the study group was lower than that in the control group

and the difference was statistically significant（ OR = 0. 45

95% CI = 0. 33-0. 62

Z = 4. 99

P < 0. 000 01）.CONCLUSIONS: Lamotrigine combined with sodium valproate in the treatment of seizure is better than valproate alone in the comprehensive efficacy and adverse drug reactions

and significantly better than that of valproate alone in reducing seizure frequency

shortening seizure duration

and lowering hypersensitive C-reactive protein levels.